Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05508633 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 25, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Primary and study completion dates: Dec 2022 to Dec 2025
    • Start date changed from estimate of Aug 2022 to Oct 28, 2022
    • Site contact updated
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this exploratory study was to investigate the instant efficacy and safety of alverine oral administration in decreasing portal hypertension. Condition of disease: Cirrhotic portal hypertension Intervention/treatment: Drug: Alverine 60 mg (1 capsule), orally Drug: Alverine 120 mg (2 capsules), orally
Trial Details
NCT Number NCT05508633
Lead Sponsor Shanghai Changzheng Hospital
Conditions
(from sponsor)		 Portal Hypertension
Related terms Hypertension, Portal
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov